About us Contacts Drug interactions: 390 212
Drug search by name

Fedratinib Hydrochloride and Lurasidone

Determining the interaction of Fedratinib Hydrochloride and Lurasidone and the possibility of their joint administration.

Check result:
Fedratinib Hydrochloride <> Lurasidone
Relevance: 24.08.2022 Reviewer: Shkutko P.M., M.D., in

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer:

Consumer information for this interaction is not currently available.ADJUST DOSE: Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of lurasidone and its active metabolite, both of which are primarily metabolized by the isoenzyme. In a pharmacokinetic study, administration of a single 20 mg dose of lurasidone with the moderate CYP450 3A4 inhibitor diltiazem (extended release formulation 240 mg/day for 5 days) resulted in a 2.1-fold increase in lurasidone peak plasma concentration (Cmax) and a 2.2-fold increase in systemic exposure (AUC) compared to administration alone. The AUC of lurasidone's active metabolite increased by 2.4-fold. The use of an immediate release formulation of diltiazem could result in a greater magnitude of interaction. MANAGEMENT: Lurasidone dosage should start at 20 mg/day and not exceed 80 mg/day when coadministered with moderate CYP450 3A4 inhibitors. If a moderate CYP450 3A4 inhibitor is added to existing lurasidone therapy, the lurasidone dosage should be reduced by half. References Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0 Cerner Multum, Inc. "Australian Product Information." O 0 "Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc, Marlborough, MA.

Professional:

ADJUST DOSE: Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of lurasidone and its active metabolite, both of which are primarily metabolized by the isoenzyme. In a pharmacokinetic study, administration of a single 20 mg dose of lurasidone with the moderate CYP450 3A4 inhibitor diltiazem (extended release formulation 240 mg/day for 5 days) resulted in a 2.1-fold increase in lurasidone peak plasma concentration (Cmax) and a 2.2-fold increase in systemic exposure (AUC) compared to administration alone. The AUC of lurasidone's active metabolite increased by 2.4-fold. The use of an immediate release formulation of diltiazem could result in a greater magnitude of interaction.

MANAGEMENT: Lurasidone dosage should start at 20 mg/day and not exceed 80 mg/day when coadministered with moderate CYP450 3A4 inhibitors. If a moderate CYP450 3A4 inhibitor is added to existing lurasidone therapy, the lurasidone dosage should be reduced by half.

References
  • Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  • Cerner Multum, Inc. "Australian Product Information." O 0
  • "Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc, Marlborough, MA.
Fedratinib Hydrochloride

Generic Name: fedratinib

Brand name: Inrebic

Synonyms: Fedratinib

Lurasidone

Generic Name: lurasidone

Brand name: Latuda

Synonyms: n.a.

In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.

Interaction with food and lifestyle
Disease interaction